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Background
Myocardial dysfunction is a recognized toxicity of
anthracycline (A) and herceptin (H) chemotherapy.
Whilst there is much current focus on the incidence
and magnitude of myocardial dysfunction following the
A/H regimen, whether these changes are mediated by
reversible or irreversible myocardial injury remains
unknown. We sought to determine rates of persistent
LV dysfunction at 12 months (as defined by left ventri-
cular ejection fraction (LVEF) decrease by 10% or below
lower limits of normal) following A/H and explore the
mechanism of myocardial dysfunction using advance
cardiac imaging.
Methods
Thirty six chemonaive patients (26 with A, 10 with H)
with breast cancer, underwent serial CMR imaging (for
LV volumes/EF, myocardial edema and necrosis) and
advanced echocardiography for global longitudinal strain
(GLS) in addition to standard measurements of LV diasto-
lic function. All tests were conducted at baseline, 1, 3 and
12 months (21 patients). Six normal volunteers underwent
the same CMR protocol. For edema imaging, short-TI
inversion recovery was used in 3 short-axis views of the
LV. Myocardial edema was assessed using Lake Louis
criteria [1].
Results
In the study patients, the mean CMR LV end-systolic
volume index (LVESVI) increased from baseline of 17.4 ±
6.1 to 26.4 ± 9.6; p value <0.001 at 12 months (Table 1).
LVEF decreased from 72.4 ± 6.4 to 64.8 ± 6.4 at 12
months; p value < 0.001. Significant functional changes
were seen as early as 1 and 3 months (table 1). Fifty
% (9/21) of patients exhibited persistent LV myocardial
systolic dysfunction at 12 months. GLS showed no signif-
icant change at 1 month, however decreased in absolute
magnitude from -21.2 ± 3% baseline to -19.2 ± 1.8% (p ≤
0.001) at 3 months. Although there was no difference
between baseline values of T2 ratio between normal
volunteers and study patients, 52% (17/33) of patients
had an abnormal T2 signal as specified by Lake Louis cri-
teria in one or more short axis slices 3 months post che-
motherapy. One patient developed new late gadolinium
hyperenhancement suggestive of focal myocardial necro-
sis/fibrosis in the trastuzumab group at 3 months follow-
ing therapy.
Conclusions
Our data suggest that the subtle functional changes in the
LV myocardium early post breast cancer chemotherapy
persist into 12 months in a significant number of pati-
ents. These changes are likely mediated by myocardial
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Table 1 Functional changes following chemotherapy
LVEDVI LVESVI LVEF LVMM RVEDVI RVESVI RVEF
Baseline
(n=33)
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inflammation, and despite absence of irreversible myocar-
dial injury, continue to 12 months post therapy. These
findings warrant caution and suggest ongoing regular fol-
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